What is it about?
In this review, we performed a meta-analysis to evaluate the efficacy and safety of fingolimod for acute ischemic stroke.The Fingolimod plus standard treatment group decreased infarct growth and improved clinical function than the standard treatment.
Featured Image
Photo by deepigoyal on Unsplash
Why is it important?
The Fingolimod plus standard treatment group decreased infarct growth and improved clinical function than the standard treatment. There was no significant difference in the incidence of complications and adverse events between the standard treatment group and fingolimod plus standard treatment group.
Perspectives
Our study shows that these early results are promising, larger studies in different patient populations are needed to validate the studies.
Jin Zhen
Inner Mongolia People's Hospital
Read the Original
This page is a summary of: The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta‐analysis, Pharmacology Research & Perspectives, May 2022, Wiley,
DOI: 10.1002/prp2.972.
You can read the full text:
Resources
Contributors
The following have contributed to this page
